Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis

BACKGROUND: A Phase I, single-center investigation found that 8 weeks of antimycobacterial therapy improved sarcoidosis FVC. Safety and efficacy assessments have not been performed in a multicenter cohort. RESEARCH QUESTION: The objective of this study was to determine the safety and efficacy of ant...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Chest
Autori principali: Drake, Wonder P., Culver, Daniel A., Baughman, Robert P., Judson, Marc A., Crouser, Elliott D., James, W. Ennis, Ayers, Gregory D., Ding, Tan, Abel, Kenny, Green, Abena, Kerrigan, Amy, Sesay, Ahmed, Bernard, Gordon R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American College of Chest Physicians 2021
Soggetti:
Diffuse Lung Disease: Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8129732/
https://ncbi.nlm.nih.gov/pubmed/33387486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2020.12.027
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi